Literature DB >> 12200392

Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations.

Sandra Bosio1, Marco De Gobbi, Antonella Roetto, Gabriella Zecchina, Eugenio Leonardo, Mario Rizzetto, Claudio Lucetti, Lucia Petrozzi, Ubaldo Bonuccelli, Clara Camaschella.   

Abstract

Aceruloplasminemia is a recessive disorder characterized by anemia, iron overload, and neurodegeneration, caused by the absence of ceruloplasmin (Cp), a multicopper oxidase important for iron export. Few patients homozygous for loss of function mutations of the Cp gene have been reported. We describe a 62-year-old white woman with heavy liver iron overload, diabetes, anemia, and neurologic symptoms. She was compound heterozygote for 2 novel mutations that result in the absence of hepatocyte Cp: an adenine insertion at nucleotide 2917 causing a truncated protein and a C-G transversion causing a glutamine-->glutamic acid substitution at position 146. Although rare in whites, aceruloplasminemia should be considered in the differential diagnosis of unexplained anemia associated with iron overload, because these features anticipate progressive neurologic symptoms. We propose that anemia, secondary to the impaired macrophage iron release, plays a major role in hepatic iron overload through increased absorption mediated by the erythroid regulator.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200392     DOI: 10.1182/blood-2002-02-0584

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

Review 2.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

3.  Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Authors:  R Mariani; C Arosio; S Pelucchi; M Grisoli; A Piga; P Trombini; A Piperno
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.

Authors:  A McNeill; D Birchall; S J Hayflick; A Gregory; J F Schenk; E A Zimmerman; H Shang; H Miyajima; P F Chinnery
Journal:  Neurology       Date:  2008-04-29       Impact factor: 9.910

Review 5.  Recent advances in understanding haemochromatosis: a transition state.

Authors:  K J H Robson; A T Merryweather-Clarke; E Cadet; V Viprakasit; M G Zaahl; J J Pointon; D J Weatherall; J Rochette
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

Review 6.  Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms.

Authors:  Daniela Berg
Journal:  Neurochem Res       Date:  2007-04-28       Impact factor: 3.996

7.  Ceruloplasmin induces polymorphonuclear leukocyte priming in localized aggressive periodontitis.

Authors:  Tomoyuki Iwata; Alpdogan Kantarci; Motohiko Yagi; Tina Jackson; Hatice Hasturk; Hidemi Kurihara; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2009-08       Impact factor: 6.993

8.  Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Authors:  Armin Finkenstedt; Elisabeth Wolf; Elmar Höfner; Bethina Isasi Gasser; Sylvia Bösch; Rania Bakry; Marc Creus; Christian Kremser; Michael Schocke; Milan Theurl; Patrizia Moser; Melanie Schranz; Guenther Bonn; Werner Poewe; Wolfgang Vogel; Andreas R Janecke; Heinz Zoller
Journal:  J Hepatol       Date:  2010-08-04       Impact factor: 25.083

9.  Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene.

Authors:  Ayako Yamamura; Yoshitaka Kikukawa; Kenji Tokunaga; Eiko Miyagawa; Shinya Endo; Hirosada Miyake; Hiroyuki Hata; Hiroaki Mitsuya; Kunihiro Yoshida; Masao Matsuoka
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271

Review 10.  Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker.

Authors:  Daniela Berg; Helmine Hochstrasser; Katherine J Schweitzer; Olaf Riess
Journal:  Neurotox Res       Date:  2006-01       Impact factor: 3.978

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.